Enliven Therapeutics, Inc. announced that it has entered into a securities purchase agreement to issue 5,357,144 shares at a price of $14 per share for the gross proceeds of $75,000,016 and pre funded warrants at a price of $13.999 per warrant for the total gross proceeds of $90,000,000 on March 19, 2024. The Pre-Funded Warrants will be exercisable into 1,071,505 shares and will have an exercise price of $0.001 per share of common stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.94 USD | +4.18% | +3.91% | +72.98% |
May. 20 | Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing | MT |
May. 14 | Enliven Therapeutics Q1 Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.98% | 1.13B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding